View More Recent Stories
-
Piper Sandler Starts Nektar Therapeutics (NKTR) at Overweight
-
Nektar Therapeutics (NKTR) Announces Publication of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases
-
Nektar Therapeutics (NKTR) Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy
-
BTIG Assumes Nektar Therapeutics (NKTR) at Buy
-
Nektar Therapeutics (NKTR) Misses Q2 EPS by 6c
-
Nektar Therapeutics (NKTR) Presents First Preclinical Data on NKTR-0165

